ONO-1110

Small molecule

Phase 2topline reported

Evidence outlook

Fibromyalgia: topline reported 2026-10-29

The sponsor reported topline results on 2026-10-29 (Ono reports Phase 2 results of ONO-1110: the PHN, fibromyalgia and HIC studies missed their primary endpoints). The announcement is listed under Regulatory events.

Development in Major Depressive Disorder stopped (2026-10-29) after a negative readout. Development continues in another indication. Source

Development in Social Anxiety Disorder stopped (2026-10-29) after a negative readout. Development continues in another indication. Source

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (5)
Fibromyalgia
Other / comorbidity
NCT06752603 · Ono Pharmaceutical Co., Ltd.
2025-04-02 – 2026-06-12 · Hunner Type Interstitial Cystitis
What this study did
NCT06708416 · Ono Pharmaceutical Co., Ltd.
2025-02-12 – 2026-05-11 · Postherpetic Neuralgia
What this study did

Competitive landscape

This drug's own stage for Fibromyalgia: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
ONO-1110: this drugPhase 2Small moleculeEndocannabinoid synthesisnot yet gradedNo reviewed efficacy summary in this indication
Cyclobenzaprine (Tonmya)ApprovedSmall molecule5-HT2A, α1-adrenergic, H1-histaminergic, and M1-muscarinic acetylcholine receptors (functional antagonism)Partial signal
NCT04172831: Change in weekly average daily pain (NRS) from baseline to week 14: TNX-102 SL 5.6 mg -1.9 vs placebo -1.5; LS mean difference -0.4 (95% CI -0.7 to -0.1), p=0.010 (n=248 and 255) (CT.gov posted results).
NCT04508621: Change From Baseline to Week 14 in the Numerical Rating Scale (NRS) Weekly Average of Daily Self-reported Average Pain Severity Scores. (14 weeks): TNX-102 SL Tablet, 5.6 mg -1.6 score on a scale (95% CI -1.8 to -1.3) | Placebo SL Tablet -1.3 score on a scale (95% CI -1.5 to -1.1) missed
Duloxetine (Cymbalta)ApprovedSmall moleculeSerotonin/norepinephrine transporter, Serotonin and norepinephrine transporters (SERT/NET)not yet gradedNo reviewed efficacy summary in this indication
PregabalinApprovedSmall moleculeα2δ subunit of voltage-gated calcium channelsnot yet gradedNo reviewed efficacy summary in this indication
EsreboxetinePhase 3Small moleculenorepinephrine transporternot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

29 October 2026Topline resultOno reports Phase 2 results of ONO-1110: the PHN, fibromyalgia and HIC studies missed their primary endpoints
Ono Pharmaceutical · Source ↗